{"id":78540,"date":"2026-09-03T17:45:57","date_gmt":"2026-09-03T09:45:57","guid":{"rendered":"https:\/\/flcube.com\/?p=78540"},"modified":"2026-09-03T17:45:58","modified_gmt":"2026-09-03T09:45:58","slug":"keymed-biosciences-grants-aeira-exclusive-rights-to-stapokibart-across-18-southeast-and-central-asia-markets-securing-high-double-digit-royalties","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78540","title":{"rendered":"Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double\u2011Digit Royalties"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Keymed Biosciences Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2162:HKG\">HKG: 2162<\/a>) announced that it has entered into an exclusive licensing agreement with multinational pharmaceutical company <strong>Aeira Pte. Ltd.<\/strong> for the marketing registration and commercialization of <strong>Stapokibart<\/strong> injection (trade name: Kangyueda; R&amp;D codename: CM310) across 18 countries and regions in Southeast Asia and Central Asia. The deal \u2014 with upfront and milestone payments plus royalties of up to a high double\u2011digit percentage \u2014 extends the global footprint of China&#8217;s approved IL\u20114R\u03b1 antibody beyond its home market.<\/p>\n\n\n\n<h2 id=\"h-deal-terms-at-a-glance\" class=\"wp-block-heading\">Deal Terms at a Glance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Parties<\/td><td><strong>Keymed Biosciences<\/strong> (HKG: 2162) and <strong>Aeira Pte. Ltd.<\/strong><\/td><\/tr><tr><td>Structure<\/td><td>Exclusive licensing agreement<\/td><\/tr><tr><td>Asset<\/td><td><strong>Stapokibart<\/strong> injection (Kangyueda \/ CM310)<\/td><\/tr><tr><td>Licensed Territory<\/td><td>18 countries and regions across Southeast Asia and Central Asia<\/td><\/tr><tr><td>Upfront Payment<\/td><td>To be received by <strong>Keymed<\/strong> (amount undisclosed)<\/td><\/tr><tr><td>Milestones<\/td><td>Approval milestones per country plus commercialization milestone payments<\/td><\/tr><tr><td>Royalties<\/td><td>Up to a high double\u2011digit percentage of net sales in the licensed territory<\/td><\/tr><tr><td>Manufacturing<\/td><td><strong>Keymed<\/strong> retains responsibility for manufacture and product supply to <strong>Aeira<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-licensed-territory-breakdown\" class=\"wp-block-heading\">Licensed Territory Breakdown<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Countries \/ Regions<\/th><\/tr><\/thead><tbody><tr><td>Southeast Asia (11)<\/td><td>Brunei Darussalam, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, the Philippines, Singapore, Thailand, Timor\u2011Leste, Vietnam<\/td><\/tr><tr><td>Central Asia (5)<\/td><td>Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan<\/td><\/tr><tr><td>Greater China Adjacent (2)<\/td><td>China&#8217;s Hong Kong SAR, Macao SAR<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Aeira<\/strong> will lead registration filings and commercialization across all 18 markets, while <strong>Keymed Biosciences<\/strong> maintains manufacturing and supply control \u2014 preserving quality assurance and a durable supply revenue stream.<\/p>\n\n\n\n<h2 id=\"h-drug-profile-amp-approved-indications\" class=\"wp-block-heading\">Drug Profile &amp; Approved Indications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Stapokibart<\/strong>, a high\u2011efficient, humanized antibody targeting the interleukin\u20114 receptor alpha subunit (IL\u20114R\u03b1)<\/li>\n\n\n\n<li><strong>Clinical Profile:<\/strong> Demonstrated good safety and encouraging efficacy across multiple previous clinical trials<\/li>\n\n\n\n<li><strong>China Approval History:<\/strong><\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>China Approval Date<\/th><\/tr><\/thead><tbody><tr><td>Moderate\u2011to\u2011severe atopic dermatitis in adults<\/td><td>September 2024<\/td><\/tr><tr><td>Chronic rhinosinusitis with nasal polyposis<\/td><td>December 2024<\/td><\/tr><tr><td>Seasonal allergic rhinitis<\/td><td>February 2025<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Multi\u2011market scale:<\/strong> Coverage of 18 countries and regions across Southeast and Central Asia \u2014 plus Hong Kong and Macao \u2014 gives <strong>Stapokibart<\/strong> one of the broader regional licensing footprints for a China\u2011originated immunology antibody<\/li>\n\n\n\n<li><strong>Royalty quality:<\/strong> Royalties of up to a high double\u2011digit percentage on net sales represent strong economics for <strong>Keymed Biosciences<\/strong>, reinforced by manufacturing and supply responsibilities<\/li>\n\n\n\n<li><strong>Proven asset:<\/strong> With three approved indications in China and a solid safety and efficacy record, <strong>Stapokibart<\/strong> enters new markets as a clinically validated IL\u20114R\u03b1 competitor rather than a development\u2011stage risk<\/li>\n\n\n\n<li><strong>Regional partner fit:<\/strong> <strong>Aeira&#8217;s<\/strong> multinational infrastructure positions it to navigate the diverse regulatory landscapes of Southeast and Central Asia, where atopic dermatitis and allergic disease prevalence continue to rise<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief contains forward\u2011looking statements regarding registration filings, approval timelines, commercialization, and royalty realization for <strong>Stapokibart<\/strong> in the licensed territory. Actual results may differ materially due to regulatory, competitive, manufacturing, and market risks. No investment decision should be made solely on the basis of this brief.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Keymed Biosciences Inc. (HKG: 2162) announced that it has entered into an exclusive licensing agreement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":78542,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10,11,4908],"tags":[4923,974,179],"class_list":["post-78540","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","category-pic","tag-aeira","tag-hkg-2162","tag-keymed-biosciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double\u2011Digit Royalties - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Keymed Biosciences Inc. (HKG: 2162) announced that it has entered into an exclusive licensing agreement with multinational pharmaceutical company Aeira Pte. Ltd. for the marketing registration and commercialization of Stapokibart injection (trade name: Kangyueda; R&amp;D codename: CM310) across 18 countries and regions in Southeast Asia and Central Asia. The deal \u2014 with upfront and milestone payments plus royalties of up to a high double\u2011digit percentage \u2014 extends the global footprint of China&#039;s approved IL\u20114R\u03b1 antibody beyond its home market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=78540\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double\u2011Digit Royalties\" \/>\n<meta property=\"og:description\" content=\"Keymed Biosciences Inc. (HKG: 2162) announced that it has entered into an exclusive licensing agreement with multinational pharmaceutical company Aeira Pte. Ltd. for the marketing registration and commercialization of Stapokibart injection (trade name: Kangyueda; R&amp;D codename: CM310) across 18 countries and regions in Southeast Asia and Central Asia. The deal \u2014 with upfront and milestone payments plus royalties of up to a high double\u2011digit percentage \u2014 extends the global footprint of China&#039;s approved IL\u20114R\u03b1 antibody beyond its home market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=78540\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-03T09:45:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-03T09:45:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0303.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78540#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78540\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double\u2011Digit Royalties\",\"datePublished\":\"2026-09-03T09:45:57+00:00\",\"dateModified\":\"2026-09-03T09:45:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78540\"},\"wordCount\":482,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78540#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0303.webp\",\"keywords\":[\"Aeira\",\"HKG: 2162\",\"Keymed Biosciences\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\",\"PIC\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78540#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78540\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=78540\",\"name\":\"Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double\u2011Digit Royalties - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78540#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78540#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0303.webp\",\"datePublished\":\"2026-09-03T09:45:57+00:00\",\"dateModified\":\"2026-09-03T09:45:58+00:00\",\"description\":\"Keymed Biosciences Inc. (HKG: 2162) announced that it has entered into an exclusive licensing agreement with multinational pharmaceutical company Aeira Pte. Ltd. for the marketing registration and commercialization of Stapokibart injection (trade name: Kangyueda; R&D codename: CM310) across 18 countries and regions in Southeast Asia and Central Asia. The deal \u2014 with upfront and milestone payments plus royalties of up to a high double\u2011digit percentage \u2014 extends the global footprint of China's approved IL\u20114R\u03b1 antibody beyond its home market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78540#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78540\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78540#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0303.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0303.webp\",\"width\":1080,\"height\":608,\"caption\":\"Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double\u2011Digit Royalties\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78540#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double\u2011Digit Royalties\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double\u2011Digit Royalties - Insight, China&#039;s Pharmaceutical Industry","description":"Keymed Biosciences Inc. (HKG: 2162) announced that it has entered into an exclusive licensing agreement with multinational pharmaceutical company Aeira Pte. Ltd. for the marketing registration and commercialization of Stapokibart injection (trade name: Kangyueda; R&D codename: CM310) across 18 countries and regions in Southeast Asia and Central Asia. The deal \u2014 with upfront and milestone payments plus royalties of up to a high double\u2011digit percentage \u2014 extends the global footprint of China's approved IL\u20114R\u03b1 antibody beyond its home market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=78540","og_locale":"en_US","og_type":"article","og_title":"Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double\u2011Digit Royalties","og_description":"Keymed Biosciences Inc. (HKG: 2162) announced that it has entered into an exclusive licensing agreement with multinational pharmaceutical company Aeira Pte. Ltd. for the marketing registration and commercialization of Stapokibart injection (trade name: Kangyueda; R&D codename: CM310) across 18 countries and regions in Southeast Asia and Central Asia. The deal \u2014 with upfront and milestone payments plus royalties of up to a high double\u2011digit percentage \u2014 extends the global footprint of China's approved IL\u20114R\u03b1 antibody beyond its home market.","og_url":"https:\/\/flcube.com\/?p=78540","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-03T09:45:57+00:00","article_modified_time":"2026-09-03T09:45:58+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0303.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=78540#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=78540"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double\u2011Digit Royalties","datePublished":"2026-09-03T09:45:57+00:00","dateModified":"2026-09-03T09:45:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=78540"},"wordCount":482,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=78540#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0303.webp","keywords":["Aeira","HKG: 2162","Keymed Biosciences"],"articleSection":["Company","Deals","Drug","PIC"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=78540#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=78540","url":"https:\/\/flcube.com\/?p=78540","name":"Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double\u2011Digit Royalties - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=78540#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=78540#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0303.webp","datePublished":"2026-09-03T09:45:57+00:00","dateModified":"2026-09-03T09:45:58+00:00","description":"Keymed Biosciences Inc. (HKG: 2162) announced that it has entered into an exclusive licensing agreement with multinational pharmaceutical company Aeira Pte. Ltd. for the marketing registration and commercialization of Stapokibart injection (trade name: Kangyueda; R&D codename: CM310) across 18 countries and regions in Southeast Asia and Central Asia. The deal \u2014 with upfront and milestone payments plus royalties of up to a high double\u2011digit percentage \u2014 extends the global footprint of China's approved IL\u20114R\u03b1 antibody beyond its home market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=78540#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=78540"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=78540#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0303.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0303.webp","width":1080,"height":608,"caption":"Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double\u2011Digit Royalties"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=78540#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double\u2011Digit Royalties"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0303.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78540"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78540\/revisions"}],"predecessor-version":[{"id":78543,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78540\/revisions\/78543"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/78542"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78540"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78540"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}